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872-3 Analysis of ST-Segment Shift in Lead AVR Improves 
Short-Term Prognostic Risk Stratification in Acute 
Coronary Syndrome 
Shunta Sakai, Jeffrey A. Gavard, Karen Stock& Bernard R. Chaitman, for the 
GUARDIAN Investigators, St. Louis University School of Medicine, St. Louis, MO 
Background: Transient ST segment elevation (STE) in lead aVR during an acute coro- 
nary syndrome (ACS) is associated with severe multivessel coronary disease but few 
studies have assessed the prognostic impact of this finding. 
Methods: The GUARDIAN trial contained 4,233 ACS pts without persistent STE and had 
prospectively acquired baseline clinical and post-randomization CK-MB and ECG data. 
In this report, pts were excluded who had intraventricular conduction defects (322), artifi- 
cial pacemaker (7). technical problems that interfered with coding (26), or had a missing 
baseline ECG tracing (21). The magnitude of ST segment shift in leads with more than 
0.5 mm ST segment displacement was assessed in the 12-lead ECG at baseline for the 
remaining 3,657 pts. Results were correlated to &month mortality. 
Results: There were 442 (11.5%) pts who had STEz1.00 mm in lead aVR. The B-month 
mortality rates were 29.2% (129/442) in pts with STE 21 .OO mm in lead aVR vs 4.6% 
(165/3,415) in pts without STE 21 .OO mm in lead aVR (pcO.001). The 6-month mortality 
rates were 29.4% (1211412) in pts with STE 51.00.~2.00 mm I” lead aVR and 26.7% (6/ 
30) in pts with STE ZOO mm in lead aVR (p=O.92). All pts with STE >I.00 mm in lead 
aVR had ST segment depression (STD) to.5 mm in other leads. There was a strong cor- 
relation between STE in lead aVR and the sum of STD in other leads (r=O.63, p<O.OOl). 
The 6-month mortality in pts with STD was 12.4% (230/1,849) vs 3.2% (64/2,006) in pts 
without STD (pcO.001). The 6.month mortality rates were 4.7% (Q/192) in pts with STD 
Zl.5-<l .OO mm, 5.6% (17/302) in pts with STD 21 .OO-~2.00 mm, and 15.0% (204/l ,356) 
in pts with STD Z2.00 mm (p<O.OOl). The 12.4% mortality for baseline STD was signifi- 
cantly less than the 29.2% mortality for baseline STE in lead aVR (pcO.001). The 6- 
month mortality rates I” pts not having STE>l .OO mm in lead aVR were 7.2% (1 Oll1407) 
if STD was present vs 3.2% (64/2,006) if STD was absent (p<O.OOl). 
Conclusions: ST elevation in lead aVR is a simple and powerful predictor of 6.month 
mortality in ACS pts. Recognition of this easily obtained ECG parameter may facilitate 
risk stratification procedures. 
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872-4 A Simple ECG Method Using High-Risk infarct Territory 
Is Superior to ECGs Using Summed ST Elevation for 
Assessing Risk in ST Elevation Myocardial Infarction 
Graham C. Wonq, Sabina A. Murphy, David A. Morrow, Robert P. Giugliano, Christopher 
P. Cannon, James de Lemos, Marc S. Sabatine, C. Michael Gibson, University of Texas 
Southwestern Medical School, Dallas, TX, The TIMI Study Group, Brigham &Women’s 
Hospital, Boston, MA 
Background: Recent ST elevation mywardial infarction (STEMI) trials (DANAMI 2) 
have used summed ST elevation CSTE) on a presenting ECG to identify patients (pts) 
for enrollment. However, ZSTE is potentially difficult to use at the bedside. In order to 
more easily identify high-risk STEMI pts at presentation, we devised a simple ECG model 
based on the presence of a high-risk infarct territory and compared its association to 30- 
day mortality withZSTE. 
Methods: We assessed ECGs from 996 pts enrolled in 2 TIMI STEMI trials blinded to 
clinical outcomes. Absolute mortality rates and odds ratios (OR) for 30-day mortality 
were calculated for pts with ZSTE from 24 through 214 mm and for pts with a high risk 
(HR) ECG (anterior myocardial infarction (Ml) or inferior Ml with ST depression >lmm in 
leads Vl or V2). 
Resufts: The presence of a HR ECG was a better discriminator for 30 day mortality than 
ZSTE of +4 and +6mm (figure, likelihood ratio test ~~0.05). A HR ECG was associ- 
ated with a higher OR for 30 day mortality compared with 5TE up to ~6mm. More 
STEMI pts were Identified using a HR ECG than with LSTEzEmm (74.9% vs 56.2%). 
Conclusions: A HR ECG is simpler to use thanZSTE, and provides superior discrimina- 
tion between high and low risk pts for 30 day mortality than ZSTE 24 and 26mm. 
Although the >8mm cut point had better performance, it only identified 56.2% of pts. 
Future clinical trials should consider using this simple HR method to identify high-risk 
STEMI pts. 
JACC March 19,2003 
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872-5 lschemia Modified Albumin (MA ) Is Useful for 
Discriminating Acute Coronary Syndromes From 
Nonischemic Presentations in the Emergency 
Department 
Manas K. Sinha, David C. Gaze, Paul 0. Collinson, Deborah L. Morris, Juan-Carlos 
Kaski. St. George’s Hospital Medical School, London, United Kingdom, lschemia 
Technologies, Denver, CO 
Introduction: ECG and myocardial necrosis biomarkers fail to identify many patients pre- 
sentlng with acute symptoms and who are at high risk for adverse cardiac events in the 
early follow-up period. A novel marker for cardiac ischaemia, lschemia Modified Albumin 
(IMA), was compared to 12 lead ECG and cardiac troponin T (cTnT) regarding early 
diagnosis of acute coronary syndromes (ACS). 206 patients presenting to the ED within 3 
hours of acute chest pain suggestive of ACS were assessed prospectively. Methods: At 
hospital presentation, ECG was recorded and blood taken for IMA and cTnT. Results of 
IMA, ECG, and cTnT, used alone and in combination models, were compared to final 
diagnosis (as determined by the managing physicians blinded to IMA results) of non- 
ischaemic chest pain (NICP), or ACS (including unstable angina, and ST segment or 
non-ST segment elevation mywardial infarction. Logistic regression was used to con- 
struct predictive models for final diagnosis. IMA and cTnT were treated as quantitative 
and ECG as qualitative. The area under the Receiver Operator Characteristic (ROC) 
curve was evaluated for each model’s ability to discriminate ACS from NICP. A p value c 
0.05 was considered significant. Conclusions: In this study, IMA was a significant addi- 
tion to presentation ECG for early discrimination of ACS from NICP in patients presenting 
to the ED with acute symptoms of cardiac ischaemia 
Logistic regression Chi square for 
model model 
IMA 23.13 
ECG 32.70 
cTnT 20.73 
ECG + cTnT 47.30 
MA + ECG 55.38 
IMA + cTnT 49.15 
fMA + ECG + cTnT 74.10 
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significant 
variables 
IMA 0.68 
ECG 0.66 
cTnT 
ECG 
IMA and ECG 
IMA and TnT 
IMA and ECG 0.83 
mea under ROC 
CUrYe 
0.64 
0.74 
0.60 
0.77 
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872-6 N-Terminal Pro-Brain Natriuretic Peptide on Admission 
Has Prognostic Value Across the Whole Spectrum of 
Acute Coronary Syndromes 
Marcello Galvani, Filippo Dttani, Ernest0 Murena, Luioi Oltrona. Patrizia Maras, Marco 
Tubaro, Aldo Maggioni, Fondazione Cardiologica “MZ Sacco’, Forli, Italy 
OBJECTIVES The study evaluated the prognostic value of single measurement of N-ter- 
minal pro brain natriuretic peptide (NT-proBNP) obtained on admission in patients admit- 
ted to the CCU with ECG evidence of myocardial ischemia. 
BACKGROUND Early risk stratification of patients with acute coronary syndromes is 
based on clinical variables, ECG, and biochemical markers of myocardial damage. The 
importance of the detection of neurohormonal activation is however incompletely 
defined. 
METHODS The NT-proBNP was measured on admission in 1756 patients admitted in 31 
italian CCUs for angina in the preceding 12 hours and ECG evidence of myccardial 
ischemia. The outcome measure was death at 30 days which occurred in 113 patients 
(6.4%). 
RESULTS The median NT-proBNP level, obtained at a median time of 3 hours after the 
qualifying angina1 episode, was 353 (107 to 1357) rig/l.. Compared to the lowest quartile, 
patients in the second, third and fourth quartiles had a relative risk of subsequent death 
of 3.5 (95% Cl: 1.3 to 9.7). 6.6 (95% Cl: 2.6 to 17.2) and 13.8 (95% Cl: 5.5 to 34.7). 
respectively. The prognostic value of NT-proBNP was similar in patients with and without 
persistent ST-segment elevation. When NT-proBNP was added to a logistic regression 
model including clinical variables, in particular Killip class, ECG and troponin T, the NT- 
proBNP levels were independently associated with prognosis.CONCLUSIONS A single 
measurement of NT-proBNP on admission improves the early risk stratification of 
patients with acute coronary syndromes with or without persistent ST-segment elevation. 
This finding suggests that activation of the cardiac neurohormonal system may be a uni- 
fying feature among patients at high risk for death after acute coronary syndromes. 
